The Fiera Capital QSSP II Investment Fund buys units at C$1.33 apiece
By Devika Patel
Knoxville, Tenn., Feb. 7 - Acasti Pharma Inc. said it settled a C$2.15 million private placement of units with the Fiera Capital QSSP II Investment Fund Inc.
The company sold units of one class A common share and one warrant at C$1.33 per unit.
Each warrant is exercisable at C$1.60 until Dec. 3, 2018. The strike price is an 11.11% premium to C$1.44, the Feb. 6 closing share price.
Proceeds will be used for capital equipment and the monetization of the POET Technology.
Acasti develops novel long-chain phospholipids used in treating chronic cardiovascular and cardiometabolic conditions.
| Issuer: | Acasti Pharma Inc.
|
| Issue: | Units of one class A common share and one warrant
|
| Amount: | C$2.15 million
|
| Price: | C$1.33
|
| Warrants: | One warrant per unit
|
| Warrant expiration: | Dec. 3, 2018
|
| Warrant strike price: | C$1.60
|
| Investor: | The Fiera Capital QSSP II Investment Fund Inc.
|
| Settlement date: | Feb. 7
|
| Stock symbol: | TSX Venture: APO
|
| Stock price: | C$1.44 at close Feb. 6
|
| Market capitalization: | C$146.99 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
